Related references
Note: Only part of the references are listed.A prospective randomized, double-blind study to evaluate the diagnostic efficacy of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in patients with well-differentiated neuroendocrine tumors: compared with 68Ga-DOTATATE
Wenjia Zhu et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)
Dual-Tracer (68Ga-DOTATOC and 18F-FDG-)-PET/CT Scan and G1-G2 Nonfunctioning Pancreatic Neuroendocrine Tumors: A Single-Center Retrospective Evaluation of 124 Nonmetastatic Resected Cases
Salvatore Paiella et al.
NEUROENDOCRINOLOGY (2022)
Sporadic Primary Pheochromocytoma: A Prospective Intraindividual Comparison of Six Imaging Tests (CT, MRI, and PET/CT Using 68Ga-DOTATATE, FDG, 18F-FDOPA, and 18F-FDA)
Abhishek Jha et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2022)
Personalized Management of Pheochromocytoma and Paraganglioma
Svenja Noelting et al.
ENDOCRINE REVIEWS (2022)
Value of 68Ga-DOTATOC and Carbidopa-Assisted 18F-DOPA PET/CT for Insulinoma Localization
Alessio Imperiale et al.
JOURNAL OF NUCLEAR MEDICINE (2022)
Reliability and Agreement of Radiological and Pathological Tumor Size in Patients with Multiple Endocrine Neoplasia Type 1-Related Pancreatic Neuroendocrine Tumors: Results from a Population-Based Cohort
Dirk-Jan van Beek et al.
NEUROENDOCRINOLOGY (2021)
Theranostics in neuroendocrine tumors: an overview of current approaches and future challenges
Julie Refardt et al.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2021)
Consensus on molecular imaging and theranostics in neuroendocrine neoplasms
Valentina Ambrosini et al.
EUROPEAN JOURNAL OF CANCER (2021)
Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms
Johannes Hofland et al.
ENDOCRINE REVIEWS (2020)
Cholecystokinin 2 Receptor Agonist 177Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study
Christof Rottenburger et al.
JOURNAL OF NUCLEAR MEDICINE (2020)
Head-to-Head Comparison of 68Ga-DOTA-JR11 and 68Ga-DOTATATE PET/CT in Patients with Metastatic, Well-Differentiated Neuroendocrine Tumors: A Prospective Study
Wenjia Zhu et al.
JOURNAL OF NUCLEAR MEDICINE (2020)
Comparison of 5 Different PET Radiopharmaceuticals for the Detection of Recurrent Medullary Thyroid Carcinoma A Network Meta-analysis
Sang-Woo Lee et al.
CLINICAL NUCLEAR MEDICINE (2020)
Innovative imaging of insulinoma: the end of sampling? A review
Emanuel Christ et al.
ENDOCRINE-RELATED CANCER (2020)
Inferior outcome of neuroendocrine tumor patients negative on somatostatin receptor imaging
Julie Refardt et al.
ENDOCRINE-RELATED CANCER (2020)
Performance of 68Ga-DOTA-Conjugated Somatostatin Receptor-Targeting Peptide PET in Detection of Pheochromocytoma and Paraganglioma: A Systematic Review and Metaanalysis
Sangwon Han et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
68Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers
Frederik L. Giesel et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer
Clemens Kratochwil et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
68Ga-DOTATOC PET/CT in the localization of head and neck paraganglioma compared with 18F-DOPA PET/CT and 123I-MIBG SPECT/CT
Alexander Stephan Kroiss et al.
NUCLEAR MEDICINE AND BIOLOGY (2019)
European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma
David Taieb et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
68Ga-Exendin-4 PET/CT Detects Insulinomas in Patients With Endogenous Hyperinsulinemic Hypoglycemia in MEN-1
Kwadwo Antwi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Role of Combined [68Ga]Ga-DOTA-SST Analogues and [18F]FDG PET/CT in the Management of GEP-NENs: A Systematic Review
Luciano Carideo et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Recent Updates on Molecular Imaging Reporting and Data Systems (MI-RADS) for Theranostic Radiotracers-Navigating Pitfalls of SSTR- and PSMA-Targeted PET/CT
Rudolf A. Werner et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Correlation of DOTATOC Uptake and Pathologic Grade in Neuroendocrine Tumors
Hilary Chan et al.
PANCREAS (2019)
64Cu-SARTATE PET Imaging of Patients with Neuroendocrine Tumors Demonstrates High Tumor Uptake and Retention, Potentially Allowing Prospective Dosimetry for Peptide Receptor Radionuclide Therapy
Rodney J. Hicks et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Small intestinal neuroendocrine tumours and fibrosis: an entangled conundrum
Anela Blazevic et al.
ENDOCRINE-RELATED CANCER (2018)
Biodistribution and Dosimetry of 18F-Meta-Fluorobenzylguanidine: A First-in-Human PET/CT Imaging Study of Patients with Neuroendocrine Malignancies
Neeta Pandit-Taskar et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Safety, Biodistribution, and Radiation Dosimetry of 68Ga-OPS202 in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase I Imaging Study
Guillaume P. Nicolas et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Sensitivity Comparison of 68Ga-OPS202 and 68Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study
Guillaume P. Nicolas et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Clinical Usefulness of F-18-Fluorodeoxyglucose Positron Emission Tomography in the Diagnostic Algorithm of Advanced Entero-Pancreatic Neuroendocrine Neoplasms
Maria Rinzivillo et al.
ONCOLOGIST (2018)
[18F]DOPA PET/ceCT in diagnosis and staging of primary medullary thyroid carcinoma prior to surgery
Sazan Rasul et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
Role of biomarker tests for diagnosis of neuroendocrine tumours
Johannes Hofland et al.
NATURE REVIEWS ENDOCRINOLOGY (2018)
Current Consensus on I-131 MIBG Therapy
Daiki Kayano et al.
NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
Localization of Insulinoma Using 68Ga-DOTATATE PET/CT Scan
Pavel Nockel et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
Head-to-Head Comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT: A Prospective Study of 59 Patients with Neuroendocrine Tumors
Camilla B. Johnbeck et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
Effect of hormone secretory syndromes on neuroendocrine tumor prognosis
Wouter T. Zandee et al.
ENDOCRINE-RELATED CANCER (2017)
Diagnostic utility of PET/CT with 18F-DOPA and 18F-FDG in persistent or recurrent medullary thyroid carcinoma: the importance of calcitonin and carcinoembryonic antigen cutoff
Ana Reyes Romero-Lluch et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
The Impact of Somatostatin Receptor-Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis
Martin Barrio et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
Somatostatin analogues labeled with copper radioisotopes: current status
Aleksandra Marciniak et al.
JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY (2017)
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid Imaging
Anders Sundin et al.
NEUROENDOCRINOLOGY (2017)
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology-Diagnosis and Prognostic Stratification
Aurel Perren et al.
NEUROENDOCRINOLOGY (2017)
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
J. Strosberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Management of neuroendocrine tumors of unknown primary
Krystallenia Alexandraki et al.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2017)
Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance
David L. H. Chan et al.
THERANOSTICS (2017)
Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach
Rudolf A. Werner et al.
THERANOSTICS (2017)
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
Arvind Dasari et al.
JAMA ONCOLOGY (2017)
Comparison of diagnostic accuracy of 111In-pentetreotide SPECT and 68Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours
S. Van Binnebeek et al.
EUROPEAN RADIOLOGY (2016)
The epidemiology of metastases in neuroendocrine tumors
Matias Riihimaeki et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
[68Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer - initial experience
Constantin Lapa et al.
ONCOTARGET (2016)
64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients
Andreas Pfeifer et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Localization of Hidden Insulinomas with 68Ga-DOTA-Exendin-4 PET/CT: A Pilot Study
Kwadwo Antwi et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Incremental Value of Liver MR Imaging in Patients with Potentially Curable Colorectal Hepatic Metastasis Detected at CT: A Prospective Comparison of Diffusion-weighted Imaging, Gadoxetic Acid-enhanced MR Imaging, and a Combination of Both MR Techniques
Hye Jin Kim et al.
RADIOLOGY (2015)
Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy
Daniel Kaemmerer et al.
ONCOTARGET (2015)
Diagnostic role of Gallium-68 DOTATOC and Gallium-68 DOTATATE PET in patients with neuroendocrine tumors: a meta-analysis
Jigang Yang et al.
ACTA RADIOLOGICA (2014)
PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature
Camilla Bardram Johnbeck et al.
FUTURE ONCOLOGY (2014)
The Glucose-Dependent Insulinotropic Polypeptide Receptor: A Novel Target for Neuroendocrine Tumor Imaging-First Preclinical Studies
Eleni Gourni et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
High Prognostic Value of 18F-FDG PET for Metastatic Gastroenteropancreatic Neuro endocrine Tumors: A Long-Term Evaluation
Haifa Bahri et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
PET and SPECT Imaging of a Radio labeled Minigastrin Analogue Conjugated with DOTA, NOTA, and NODAGA and Labeled with 64Cu, 68Ga, and 111In
S. Roosenburg et al.
MOLECULAR PHARMACEUTICS (2014)
18F-Fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type
Sona Balogova et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2013)
Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours
Stefano Severi et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2013)
Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis
Hakan Geijer et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2013)
Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT Within Patients with Gastroenteropancreatic Neuroendocrine Tumors
Damian Wild et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
Measured Human Dosimetry of 68Ga-DOTATATE
Ronald C. Walker et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study
Emanuel Christ et al.
LANCET DIABETES & ENDOCRINOLOGY (2013)
Clinical PET of Neuroendocrine Tumors Using 64Cu-DOTATATE: First-in-Humans Study
Andreas Pfeifer et al.
JOURNAL OF NUCLEAR MEDICINE (2012)
Unexpected Sensitivity of sst2 Antagonists to N-Terminal Radiometal Modifications
Melpomeni Fani et al.
JOURNAL OF NUCLEAR MEDICINE (2012)
Evaluation of 177Lu-DOTA-sst2 Antagonist Versus 177Lu-DOTA-sst2 Agonist Binding in Human Cancers In Vitro
Renzo Cescato et al.
JOURNAL OF NUCLEAR MEDICINE (2011)
Incremental Value of 111-In Pentetreotide SPECT/CT Fusion Imaging of Neuroendocrine Tumors
Ka Kit Wong et al.
ACADEMIC RADIOLOGY (2010)
Internalized Somatostatin Receptor Subtype 2 in Neuroendocrine Tumors of Octreotide-Treated Patients
Jean Claude Reubi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Limited Value of 18F-F-DOPA PET to Localize Pancreatic Insulin-Secreting Tumors in Adults with Hyperinsulinemic Hypoglycemia
L. Tessonnier et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Exendin-4-Based Radiopharmaceuticals for Glucagonlike Peptide-1 Receptor PET/CT and SPECT/CT
Damian Wild et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
In vivo binding of [Ga-68]-DOTATOC to somatostatin receptors in neuroendocrine tumours - impact of peptide mass
Irina Velikyan et al.
NUCLEAR MEDICINE AND BIOLOGY (2010)
Impact of Fluorodihydroxyphenylalanine-(18F) Positron Emission Tomography on Management of Adult Patients with Documented or Occult Digestive Endocrine Tumors
Francoise Montravers et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Glucagon-like peptide 1-receptor scans to localize occult insulinomas
Damian Wild et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Biology of incretins: GLP-1 and GIP
Laurie L. Baggio et al.
GASTROENTEROLOGY (2007)
68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors:: Comparison with somatostatin receptor scintigraphy and CT
Michael Gabriel et al.
JOURNAL OF NUCLEAR MEDICINE (2007)
Staging of carcinoid tumours with 18F-DOPA PET:: a prospective, diagnostic accuracy study
Klaas P. Koopmans et al.
LANCET ONCOLOGY (2006)
Peptide receptors as molecular targets for cancer diagnosis and therapy
JC Reubi
ENDOCRINE REVIEWS (2003)
Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting
JC Reubi et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2003)
Detection of small, functional islet cell tumors in the pancreas: Selection of MR imaging sequences for optimal sensitivity
RF Thoeni et al.
RADIOLOGY (2000)
Share Paper
